Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN AstraZeneca	$68.46 -7.4%	$73.97	$62.75 ▼ $87.68	$212.31B	0.49	5.15 million shs	9.21 million shs
BNTX BioNTech	$88.05 -4.3%	$109.42	$76.53 ▼ $131.49	$21.13B	1.07	839,386 shs	1.04 million shs
GILD Gilead Sciences	$107.25 -4.6%	$107.02	$62.07 ▼ $119.96	$133.54B	0.32	7.35 million shs	12.92 million shs
MRNA Moderna	$25.11 -2.4%	$33.88	$23.79 ▼ $170.47	$9.71B	2.23	7.01 million shs	16.04 million shs
PFE Pfizer	$22.99 -5.4%	$25.93	$22.97 ▼ $31.54	$130.39B	0.61	39.47 million shs	79.83 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN AstraZeneca	+2.35%	+1.48%	-4.31%	+11.58%	+10.64%
BNTX BioNTech	-1.40%	-3.55%	-16.09%	-20.54%	+1.35%
GILD Gilead Sciences	+0.45%	+1.11%	-2.05%	+22.95%	+58.54%
MRNA Moderna	-7.18%	-19.89%	-15.28%	-39.00%	-74.58%
PFE Pfizer	-1.76%	-3.02%	-5.52%	-8.63%	-10.78%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZN AstraZeneca	3.5716 of 5 stars	3.6	5.0	1.7	0.0	3.6	0.0	1.3
BNTX BioNTech	2.6587 of 5 stars	4.4	2.0	0.0	0.0	2.4	0.8	0.6
GILD Gilead Sciences	4.4648 of 5 stars	2.4	4.0	1.7	4.1	3.5	2.5	1.9
MRNA Moderna	4.226 of 5 stars	4.0	1.0	0.0	4.6	2.0	2.5	1.3
PFE Pfizer	4.9669 of 5 stars	3.3	3.0	4.2	4.2	3.3	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN AstraZeneca	3.10	Buy	$89.75	31.10% Upside
BNTX BioNTech	2.89	Moderate Buy	$143.44	62.90% Upside
GILD Gilead Sciences	2.72	Moderate Buy	$105.12	-1.99% Downside
MRNA Moderna	2.04	Hold	$59.00	134.97% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	38.86% Upside

Current Analyst Ratings Breakdown

Latest AZN, PFE, BNTX, MRNA, and GILD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/1/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$150.00 ➝ $145.00
3/27/2025	PFE Pfizer	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/27/2025	GILD Gilead Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$120.00 ➝ $130.00
3/21/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$40.00 ➝ $33.00
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/13/2025	BNTX BioNTech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$145.00
3/13/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/11/2025	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$145.00 ➝ $139.00
3/11/2025	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$171.44 ➝ $171.44
3/11/2025	BNTX BioNTech	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$130.00 ➝ $143.00

(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN AstraZeneca	$54.07B	3.93	$5.81 per share	11.79	$13.18 per share	5.19
BNTX BioNTech	$2.75B	7.68	$3.79 per share	23.25	$92.17 per share	0.96
GILD Gilead Sciences	$28.75B	4.64	$8.47 per share	12.66	$15.44 per share	6.95
MRNA Moderna	$3.20B	3.03	N/A	N/A	$28.33 per share	0.89
PFE Pfizer	$63.63B	2.05	$3.60 per share	6.38	$15.81 per share	1.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN AstraZeneca	$7.04B	$2.26	30.29	13.69	1.42	13.01%	32.23%	12.31%	4/29/2025 (Estimated)
BNTX BioNTech	$1.01B	-$3.00	N/A	N/A	N/A	-15.16%	-2.35%	-2.05%	5/5/2025 (Estimated)
GILD Gilead Sciences	$480M	$0.37	289.86	13.22	0.71	1.67%	31.63%	10.38%	4/24/2025 (Estimated)
MRNA Moderna	-$3.56B	-$9.28	N/A	N/A	N/A	-110.04%	-28.74%	-21.83%	5/1/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	16.31	7.59	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)

Latest AZN, PFE, BNTX, MRNA, and GILD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	N/A	MRNA Moderna	-$2.90	N/A	N/A	N/A	$130.35 million	N/A
4/29/2025	N/A	AZN AstraZeneca	$1.10	N/A	N/A	N/A	$13.71 billion	N/A
4/29/2025	N/A	PFE Pfizer	$0.67	N/A	N/A	N/A	$14.43 billion	N/A
4/24/2025	N/A	GILD Gilead Sciences	$1.73	N/A	N/A	N/A	$6.77 billion	N/A
3/10/2025	Q4 24	BNTX BioNTech	$0.38	$1.08	+$0.70	$1.15	$1.24 billion	$1.19 billion
2/11/2025	Q4 2024	GILD Gilead Sciences	$1.67	$1.90	+$0.23	$1.42	$7.15 billion	N/A
2/6/2025	Q4 2024	AZN AstraZeneca	$1.10	$1.05	-$0.05	$0.48	$14.19 billion	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN AstraZeneca	$2.06	3.01%	+1.98%	91.15%	N/A
BNTX BioNTech	$1.53	1.74%	N/A	N/A	N/A
GILD Gilead Sciences	$3.16	2.95%	+2.74%	854.05%	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	7.48%	+2.50%	121.99%	16 Years

Latest AZN, PFE, BNTX, MRNA, and GILD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/5/2025	GILD Gilead Sciences	quarterly	$0.79	3%	3/14/2025	3/14/2025	3/28/2025
2/6/2025	AZN AstraZeneca	semi-annual	$1.03	2%	2/21/2025	2/21/2025	3/24/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN AstraZeneca	0.65	0.93	0.74
BNTX BioNTech	0.01	7.33	7.21
GILD Gilead Sciences	1.24	1.50	1.20
MRNA Moderna	N/A	3.67	3.62
PFE Pfizer	0.63	1.00	0.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN AstraZeneca	20.35%
BNTX BioNTech	15.52%
GILD Gilead Sciences	83.67%
MRNA Moderna	75.33%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
AZN AstraZeneca	N/A
BNTX BioNTech	19.20%
GILD Gilead Sciences	0.16%
MRNA Moderna	11.00%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN AstraZeneca	83,500	3.10 billion	N/A	Optionable
BNTX BioNTech	3,080	239.97 million	193.71 million	Optionable
GILD Gilead Sciences	17,000	1.25 billion	1.24 billion	Optionable
MRNA Moderna	3,900	386.62 million	324.40 million	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable

AZN, PFE, BNTX, MRNA, and GILD Headlines

Recent News About These Companies

Pfizer (NYSE:PFE) Stock Price Up 0.2% - Here's Why

April 4 at 4:48 PM | marketbeat.com

4 Blue Chip Pharmaceutical High-Yield Dividend Stocks Are Tariff Winners

April 4 at 4:44 PM | 247wallst.com

Entwistle & Cappucci LLP Files a Securities Class Action Against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC and Pfizer, Inc.

April 4 at 2:03 PM | businesswire.com

Pfizer Inc. (PFE) – Jim Cramer Declares: ‘Dead Money – Close the Casket!’

April 4 at 11:54 AM | insidermonkey.com

Pfizer (PFE) and GSK Reach Settlement in RSV Vaccine Patent Dispute

April 4 at 9:15 AM | gurufocus.com

Pfizer, GSK settle patent lawsuit over RSV vaccines

April 4 at 8:30 AM | seekingalpha.com

Foundry Partners LLC Invests $21 Million in Pfizer Inc. (NYSE:PFE)

April 4 at 6:01 AM | marketbeat.com

Arete Wealth Advisors LLC Boosts Position in Pfizer Inc. (NYSE:PFE)

April 4 at 5:33 AM | marketbeat.com

Westpac Banking Corp Has $2.72 Million Stake in Pfizer Inc. (NYSE:PFE)

April 4 at 5:23 AM | marketbeat.com

Clearbridge Investments LLC Reduces Stock Holdings in Pfizer Inc. (NYSE:PFE)

April 4 at 4:15 AM | marketbeat.com

GSK resolves patent lawsuit against Pfizer over RSV vaccines

April 3 at 6:03 PM | reuters.com

JNJ vs. PFE: Which Drug Giant is a Better Buy Now?

April 3 at 11:00 AM | zacks.com

Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna

April 3 at 8:30 AM | fool.com

Pfizer Inc. (NYSE:PFE) Shares Purchased by Huber Capital Management LLC

April 3 at 6:50 AM | marketbeat.com

Uniting Wealth Partners LLC Buys New Holdings in Pfizer Inc. (NYSE:PFE)

April 3 at 6:48 AM | marketbeat.com

Allen Wealth Management LLC Reduces Holdings in Pfizer Inc. (NYSE:PFE)

April 3 at 6:30 AM | marketbeat.com

OneAscent Financial Services LLC Acquires 11,447 Shares of Pfizer Inc. (NYSE:PFE)

April 3 at 5:48 AM | marketbeat.com

Cinctive Capital Management LP Has $4.81 Million Stock Position in Pfizer Inc. (NYSE:PFE)

April 3 at 5:47 AM | marketbeat.com

Is Pfizer Stock a Buy?

April 3 at 5:47 AM | fool.com

Huntington National Bank Sells 71,695 Shares of Pfizer Inc. (NYSE:PFE)

April 3 at 5:39 AM | marketbeat.com

2 Absurdly Cheap Stocks to Buy and Hold for Years

April 3 at 4:40 AM | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
By Jea Yu | March 11, 2025
View Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
By Gabriel Osorio-Mazilli | April 1, 2025
View 2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

AZN, PFE, BNTX, MRNA, and GILD Company Descriptions

AstraZeneca NASDAQ:AZN

$68.46 -5.46 (-7.39%)

Closing price 04:00 PM Eastern

Extended Trading

$68.55 +0.09 (+0.13%)

As of 07:00 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

BioNTech NASDAQ:BNTX

$88.05 -3.96 (-4.30%)

Closing price 04:00 PM Eastern

Extended Trading

$88.06 +0.01 (+0.01%)

As of 06:38 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Gilead Sciences NASDAQ:GILD

$107.25 -5.14 (-4.57%)

Closing price 04:00 PM Eastern

Extended Trading

$106.50 -0.75 (-0.70%)

As of 07:04 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Moderna NASDAQ:MRNA

$25.11 -0.62 (-2.41%)

Closing price 04:00 PM Eastern

Extended Trading

$25.08 -0.03 (-0.12%)

As of 07:04 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer NYSE:PFE

$22.99 -1.30 (-5.35%)

Closing price 03:59 PM Eastern

Extended Trading

$22.96 -0.02 (-0.11%)

As of 07:05 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AZN, PFE, BNTX, MRNA, and GILD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AZN, PFE, BNTX, MRNA, and GILD Earnings

Compare Dividends

Latest AZN, PFE, BNTX, MRNA, and GILD Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AZN, PFE, BNTX, MRNA, and GILD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AZN, PFE, BNTX, MRNA, and GILD Company Descriptions

AstraZeneca NASDAQ:AZN

BioNTech NASDAQ:BNTX

Gilead Sciences NASDAQ:GILD

Moderna NASDAQ:MRNA

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools